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Abstract
Objectives:  To determine the effects of isoflavones (soy phyto-estrogens) on serum total
cholesterol (TC), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol
(HDL) and triglyceride (TG).
Methods: We searched electronic databases and included randomized trials with isoflavones
interventions in the forms of tablets, isolated soy protein or soy diets. Review Manager 4.2 was
used to calculate the pooled risk differences with fixed effects model.
Results: Seventeen studies (21 comparisons) with 853 subjects were included in this meta-analysis.
Isoflavones tablets had insignificant effects on serum TC, 0.01 mmol/L (95% CI: -0.17 to 0.18,
heterogeneity p = 1.0); LDL, 0.00 mmol/L (95% CI: -0.14 to 0.15, heterogeneity p = 0.9); HDL, 0.01
mmol/L (95% CI: -0.05 to 0.06, heterogeneity p = 1.0); and triglyceride, 0.03 mmol/L (95% CI: -0.06
to 0.12, heterogeneity p = 0.9). Isoflavones interventions in the forms of isolated soy protein (ISP),
soy diets or soy protein capsule were heterogeneous to combine.
Conclusions: Isoflavones tablets, isolated or mixtures with up to 150 mg per day, seemed to have
no overall statistical and clinical benefits on serum lipids. Isoflavones interventions in the forms of
soy proteins may need further investigations to resolve whether synergistic effects are necessary
with other soy components.
Introduction
In recent years, phytoestrogens have attracted a great deal
of interests in the medical and scientific literature. It also
appears in the lay press for its effects on cardiovascular
and menopausal health, and even cancer prevention.
These compounds are present in large quantities in soy-
beans, clover and some legumes. Because of resemblances
to human estrogen and the observations that Asian popu-
lations who consume more isoflavones compared with
women in western countries have less menopausal symp-
toms, isoflavones are postulated as natural products that
may be beneficial to postmenopausal women in cardio-
vascular health. Commercial products containing differ-
ent quantities and mixtures of isoflavones are now widely
available. A meta-analysis of soy protein in 1995 found
significant cholesterols lowering effects when compared
with animal proteins [1]. The authors suggest that isofla-
vones may be the principal physiologically active compo-
nents responsible for the lipid lowering effects. However,
it is still controversial [5]. Many reviews and editorials
Published: 19 November 2003
Nutrition Journal 2003, 2:15
Received: 19 September 2003
Accepted: 19 November 2003
This article is available from: http://www.nutritionj.com/content/2/1/15
© 2003 Yeung and Yu; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/15
Page 2 of 8
(page number not for citation purposes)
[2,3] have discussed the relevance of phytoestrogens on
cardiovascular health and hypocholesterolemic effects but
there was no meta-analysis up to our searching.
Methods
Searching strategy
We searched the databases from ACP Journal Club 1991
to Oct 2002, Cochrane Controlled Trials Register 3rd
Quarter 2002, Cochrane Database of Systematic Reviews
4th Quarter 2002, Database of Abstracts of Reviews of
Effectiveness 4th Quarter 2002, British Nursing Index
(BNI) 1994 to Oct 2002, CANCERLIT 1975 to Oct 2002,
CINAHL 1982 to Oct Week 4 2002, CSA – Life Sciences
Collection 1982 to Oct 2002, EMBASE 1980 to 2002
Week 45, International Pharmaceutical Abstracts 1970 to
Oct 2002, PREMEDLINE Oct 27, 2002, MEDLINE 1996 to
Oct Week 4 2002. We searched the keywords with Ovid
software version rel6.2.0: 'soy', 'soy protein', 'soybean',
'tofu', 'phytoestrogen', 'isoflavone', 'genistein', 'daidzein',
'formononectin' and 'biochanin A' by the method
described by Dickersin 1994 [4]. We did not restrict any
languages during the searching. Hand searching was made
by retrieving relevant articles from the obtained studies
and unpublished data were obtained through contacting
experts. We identified on-going trials by searching Clini-
calTrials.gov, the UK National Research Register and
Meta-register of controlled trials on the internet.
Selection of eligible trials
We included both single and double blind randomized
controlled trials with baseline and after treatment values
for synthesizing risk (mean) differences. The outcome
measures were differences of serum total cholesterol (TC),
low density lipoprotein cholesterol (LDL-C), high density
lipoprotein cholesterol (HDL-C) and triglycerides (TG)
between post-randomization baselines and after treat-
ments. Eligible interventions were isoflavones tablets of
single isolated component or any mixtures of genisteins,
daidzein, formononectin and biochanin A. Isoflavones
interventions in forms of soy protein supplements or diets
were also included as long as they compared isoflavones
containing treatments with isoflavones depleting con-
trols. Treatments with soy polysaccharides, fiber, and phy-
tosterols as their primary interventions were excluded.
Validity assessment and data abstraction
Two independent investigators reviewed the articles
obtained without masking. There were no scorings to the
included trials. Data were entered twice to reduce input
errors. Inter-rater reliability was not performed. Data were
abstracted with a designed form before analysis. Dupli-
cated trials or studies with the same population were
counted once to reduce the duplicated publication bias.
Data disagreement between the two reviewers was
resolved by discussion.
Study characteristics
The characteristics of the obtained studies were tabulated
with subtypes of isoflavones interventions, subjects'
serum lipids status, dosages of isoflavones and lengths of
treatment. Sub-group analysis was performed with differ-
ent forms of isoflavones interventions, such as isolated
genistein or mixtures of isoflavones tablets versus pla-
cebo, isoflavones containing versus depleting soy protein
diets. Sensitivity analysis was also made across different
population characteristics and lengths of treatment. Fun-
nel plots were used to detect possible publication bias or
treatment heterogeneity across sample sizes.
Quantitative data synthesis
We obtained the risk differences (RD) from the post-ran-
domization baselines and after-treatment values in each
trial and calculated the pooled standard deviation of the
RD as:
where n1 and SD1 were sample size and standard deviation
from treatment and n2 and SD2 were from control. Inverse
variance method was used to pool all trial results [6] with
software 'Review Manager 4.2 [31]. Fixed-effects model
was used as the method of combination and it was sup-
plemented with random-effects model if necessary. Since
log odds ratios were not available in the trials, funnel
plots were plotted with standard errors against risk
(mean) differences.
Results
Trial flow
The trial flow chart was illustrated in Figure 1. Seventeen
studies [7-23] (21 comparisons) with 853 subjects were
included in this meta-analysis. Reasons for exclusion were
non-randomization, lack of control [24-27], insufficient
original data and baseline values [28,29].
Study characteristics
The characteristics of the trials included were shown in
Table 1. The populations being studied were adults of age
between 18 and 73. Soy phytoestrogens interventions var-
ied from isoflavones tablets to isoflavones containing soy
diets. Isoflavones tablets were introduced in 11 trials, soy
capsule in 1 trial, isolated soy protein (ISP) in 3 trials, and
soy foods in 2 trials. The average intake of isoflavones was
73 mg per day (ranging from 28.5 to 150 mg) and length
of treatment was 10 weeks (ranging from 2 to 26 weeks).
Three trials recruited hyperlipidemic subjects while 8
included participants with normolipidemia. Thirteen
studies recruited female, two recruited male and two
recruited subjects with both genders.
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Quantitative data synthesis
We found that isoflavones tablets insignificantly
increased serum TC by 0.01 mmol/L (95% CI = -0.17 to
0.18; heterogeneity p = 1.0) (Figure 2); LDL by 0.00
mmol/L (95% CI = -0.14 to 0.15; heterogeneity p = 0.9);
HDL by 0.01 mmol/L (95% CI = -0.05 to 0.06; heteroge-
neity p = 1.0); and triglyceride by 0.03 mmol/L (95% CI =
-0.06 to 0.12; heterogeneity p = 0.9). Isoflavones contain-
ing soy biscuits or burger had insignificant effects on
serum TC with reference to isoflavones depleting soy bis-
cuits or burger. Only isoflavones containing isolated soy
protein (ISP) or soy protein (SP) capsule reduced serum
TC when compared with isoflavones depleting ISP or SP
capsule (Table 2). There was only one trial [11] intro-
duced SP capsule as treatment. Mixtures of the four soy
phytoestrogens (genistein, daidzein, formononectin and
biochanin A) or isolated genistein did not have significant
effects on serum TC. The significant result from interven-
ing the mixtures of genistein and daidzein had shown to
be statistically heterogeneous to combine (heterogeneity
p = 0.06) as genistein and daidzein tablets were intro-
duced among 3 studies [9,10,16] while Sanders [19] chose
genistein and daidzein soy burger and Urban [22] used
genistein and daidzein ISP. In subgroup analysis, the
effect of genistein and daidzein tablets on serum TC from
the 3 studies was shown to be insignificant, 0.1 mmol/L
(95% CI = -0.25 to 0.45; heterogeneity p = 0.87). Dose-
response effect was not found in any forms of interven-
tions in this meta-analysis. The results remained insignif-
icant when the length of treatment increased. Although
one trial [22] (without washout period) produced signifi-
cant effect, it seemed that study design had no influence
on the serum TC. There were insignificant decreases of
serum TC among pre- and postmenopausal women. Inter-
estingly, cholesterol lowering effects could only be found
among normolipidemic subjects but not participants with
hyperlipidemia and men were shown to be benefited with
isoflavones treatment. Isoflavones in the forms of tablets
and ISP were all insignificant on serum low density lipo-
protein cholesterol (LDL), high density lipoprotein cho-
lesterol (HDL) and triglycerides (TG). These results were
shown in Table 3. Funnel plots of isoflavones tablets were
asymmetrical and the results of the published trials
tended to favor treatment.
Discussion
Main findings
Phytoestrogens with either isolated genistein or isofla-
vones mixtures of genistein, daidzein, formononectin and
biochanin A were found to be statistically insignificant in
lowering serum total cholesterol (Table 2). Resolving the
heterogeneity from pooling the mixtures of genistein and
daidzein, we found that tablets prescription with these
two isoflavones [9,10,16] yielded insignificant benefits
over serum TC, 0.1 mmol/L (95% CI = -0.25 to 0.45; het-
erogeneity p-value = 0.87). One trial [19], introducing soy
burger as the prescription of these 2 isoflavones, found
insignificant benefits. Another trial [22], prescribing them
in the form of isolated soy protein (ISP), had shown a
decrease in serum TC by 0.43 mmol/L (95% CI = -0.73 to
-0.13). It may be a result of bias as this trial lacked a wash-
out period. When dose-response effect and treatment
length were taken into account, phytoestrogens seemed to
have insignificant effects over serum cholesterol (Table 2).
Isoflavones in the forms of tablets, soy burger or biscuits
seemed to have insignificant benefits over serum TC. Only
Han [11] reported a significant benefit for isoflavones in
the form of soy protein capsule. Isoflavones in the forms
of tablets or ISP could not be shown to have significant
benefits over serum low density lipoprotein (LDL) choles-
terol, high density lipoprotein (HDL) cholesterol and trig-
lycerides (TG) (Table 3).
We could not demonstrate significant benefits with all
types of prescriptions when the dosages or treatment
lengths increased. No dose-response effect was detected
nor benefits on serum cholesterol with any forms of pre-
scription among pre- and post-menopausal women and
Trial flow chart of including isoflavones studies Figure 1
Trial flow chart of including isoflavones studies. Data-
bases generated 3542 potential eligible randomized control-
led trials (RCT). After careful review, seventeen RCT 
(reference [7-23]) were included in this meta-analysis.
Potentially relevant RCTs identified 
and screened for retrieval (n = 3542 )
RCTs excluded because of non-human 
study, review, no isoflavones in the 
intervention or no lipids as the outcome 
( n = 3519 )
Potentially appropriate RCTs to be 
included in the meta-analysis   
(n = 23 ) 
RCTs excluded from meta-analysis 
because of non-randomization, lack of 
placebo (n = 4 )
 [24-27]
RCTs included in meta-analysis   
( n = 19 ) 
RCTs withdrawn, by outcome, because of 
no baseline value, no enough data to 
generate treatment and placebo effects 
( n = 2 )
[28,29]
RCTs with usable information, by 
outcome ( n = 17 )
 [7-23]Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/15
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hyperlipidemic subjects. The benefit over normolipi-
demic subjects was heterogeneous (p = 0.08). It may be
again the result of prescription diversity. Separated analy-
sis found that isoflavones tablets [12,18,21] had insignif-
icant effect on serum TC among normolipidemic subjects,
0.05 mmol/L (95% CI = -0.23 to 0.33; heterogeneity p =
0.9). Only isoflavones in the form of soy protein capsule
[11] or ISP [22] reported benefits on participants with
normolidemia. In fact, some suggest that the beneficial
effects of soy protein require synergistic reactions between
isoflavones and other soy components [32]. This hypoth-
esis was supported by some animal experiments [33-35].
It seemed that isoflavones in the form of tablets, up to 150
mg per day (genistein about 50 mg, daidzein about 50
mg), had no significant benefits on serum cholesterols in
this meta-analysis. Phytoestrogens treatments in forms of
soy protein supplements or soy protein capsule may need
further investigations, especially interactions between
other chemically active components inside prescriptions.
Validity and limitation
In subgroup analysis, the sample sizes were inevitably
reduced and there might be insufficient power to detect
small significant differences. Isoflavones treatments with
dosages beyond 150 mg per day or treatment lengths
beyond 26 weeks could not be shown in this study. The
effects on serum cholesterols among subjects with hyper-
tension, diabetes mellitus or other cardiovascular risk fac-
tors were also beyond this meta-analysis. Generalizability
over other phytoestrogens such as coumestans, lignans
Funnel plot of risk difference of isoflavones tablets versus placebo on serum total cholesterol Figure 2
Funnel plot of risk difference of isoflavones tablets versus placebo on serum total cholesterol. Total treatment 
size was 274 and total control was 208. The pooled risk difference of isoflavones tablets versus placebo was 0.01 with 95% 
confidence interval between -0.17 and 0.18. Heterogeneity p-value was 1.00. Note: 'N' = sample size; 'SD' = standard deviation; 
'RD' = risk difference; '95% CI' = 95% confidence interval
Study    N Treatment N  Control  RD  (mmol/L)  Weight RD  95%  CI 
   Mean (SD)   Mean (SD)  95% CI  (%)  (fixed)  
                
Clifton 2001(I)
 [8]  16 0.21  (1.05) 15 0.30 (0.75) 7.44 -0.09 (-0.73,  0.55)
Clifton 2001(II) 
[8]  15 0.33  (0.97) 15 0.30 (0.75) 7.90  0.03 (-0.59,  0.65)
Dewell 2002
 [9]  20 -0.40  (0.89)  16 -0.30 (1.52) 4.30  -0.10 (-0.94,  0.74)
Hale 2002 
[10]  16 0.38  (0.71) 13 0.22 (0.62) 12.96  0.16 (-0.32,  0.64)
Hodgson 1998 
[12] 30  -0.06  (1.26)  29  0.00 (0.81) 10.48  -0.06 (-0.60,  0.48)
Howes 2000
 [13]  66 -0.21  (1.00)  9 -0.09 (1.25) 4.19  -0.12 (-0.97,  0.73)
Nestel 1997
 [16]  21 -0.17  (0.94)  21 -0.29 (1.12) 7.77  0.12 (-0.51,  0.75)
Nestle 1999 (I)
 [17] 13  -0.05  (0.83)  13  0.15 (0.90) 6.86  -0.20 (-0.87,  0.47)
Nestle 1999 (II)
 [17] 13  -0.02  (0.96) 13 0.15 (0.90) 5.94 -0.17 (-0.89,  0.55)
Samman 1999
 [18] 14  -0.03  (0.64)  14  -0.11 (0.70) 12.32 0.08 (-0.42,  0.58)
Simon 2000
 [20]  20 -0.41  (1.30)  20 -0.34 (1.26) 4.83  -0.07 (-0.86,  0.72)
Squadrito 2002
 [21] 30 0.20  (1.01) 30 0.10 (0.75) 15.00  0.10 (-0.35,  0.55)
Total (95% CI)  274
    
208 100.00 0.01 (-0.17,  0.18)
Test of heterogeneity: χ
2 =1.70, df = 11, p = 1.00 
 Favors 
treatment 
Favors 
control Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/15
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and resveratrol may need further trials to clarify the ques-
tions. No funnel plots were shown in this study because
the choice of risk differences as the horizontal axes may
lead to funnel plot asymmetry [36]. Publication bias was
still possible although vigorous searching had been
attempted.
Biological plausibility
It was suggested that isoflavones readily bind estrogen
receptors – beta (ER-beta) which are an important recep-
tors in both the central nervous and cardiovascular sys-
tems [37-39]. Isoflavones may also have anti-oxidant
effects on blood vessels [40-42]. However, compared with
estradiol, isoflavones bind estrogen receptors with 100
and 1,000 times less affinity [30]. Both conjugated and
aglycone forms of daidzein and genistein are rapidly
cleared from the plasma following a single dose of isofla-
vones [43] and urinary excretion is virtually nil within 48
hours after ingestion [44,45]. Biological effects of soy phy-
toestrogens are still controversial. The hypothesis from an
influential meta-analysis [1] stating soy estrogens may be
responsible for the lipid reduction effects was criticized
for the fact that the trials involved largely isoflavone-free
soy protein products [46]. Apart from phytoestrogens, in
fact, some other components such as phytic acid,
saponins and fibers were potential candidates responsible
for the hypocholesterolemic effects [32,48,49].
Suggestion to future trials
Tablets of single isolated isoflavone with considerable
dosages may be important in future randomized trials.
Intervention with isoflavones mixtures may be helpful but
interactions between components should be handled
with extra cares. Introduction of phytoestrogens in forms
of soy diets is not suggested because we found much het-
erogeneity inside the diets, ranging from soy biscuits to
burger, which may be difficult to combine and analyze.
Confounding factors such as fiber, fatty acids, amino acids
and energy intake are especially hard to control. Compli-
cations associated with hyperlipidemia, such as coronary
Table 1: Characteristics of the 17 included studies. There were 9 crossover and 8 parallel studies. The isoflavones tablets introduced 
were mainly in aglycone form. The abbreviations were listed below table.
Study Treatment 
(Rx) †
Isoflavones content 
in Rx (mg/d) ‡
Control Isoflavones 
content in 
control (mg/d)
No. of 
subjects
Lipid status § Subject 
gender ||
Length of 
treatment 
(weeks)
*Calvert 1981 [7] soy biscuits NA soy biscuits 0 10 H male 4
Clifton-Bligh 2001(I) 
[8]
T5 7T
Clifton-Bligh 2001(II) 
[8]
T 85.5 28.5 46 B female 26
Dewell 2002 [9] T 150 G = 40; D = 50; 
glycosides = 60
placebo 0 36 H female 24
Hale 2002 [10] T 80 G = 40; D = 40 placebo 0 29 NS post 2
Han 2002 [11] soy protein 
capsule
100 G = 70; D = 18; 
glycitein = 12
soy protein 
capsule
0 78 N peri 16
Hodgson 1998 [12] T 55 G = 30; D = 1; B = 
16; F = 8
placebo 0 59 N male & female 8
Howes 2000 [13] T 40 G = 1; D = 0.5; B = 
26; F = 16
placebo 0 75 NS post 5
Mackey 2000 [14] ISP 65 ISP < 4 49 H post 12
*Merz-Demlow 
2000(I) [15]
ISP 113–144 ISP
*Merz-Demlow 
2000(II) [15]
ISP 55–74 9–11 13 N female 3
*Nestel 1997 [16] T 40–80 G= 22–43; D = 
17–33; glycitein= 1–3
placebo 0 21 B female 5
*Nestel 1999(I) [17] T 80 G = 8; D = 7; B = 49; 
F = 16
placebo
*Nestel 1999(II) [17] T 40 G = 4; D = 3.5; B = 
24.5; F = 8
0 13 B female 5
*Samman 1999 [18] T 86 G = 8.6; D = 7.4; B = 
51.4; F = 18.6
placebo 0 14 N pre 16
*Sanders 2002 [19] soy burger 56 G = 34.8; D = 21.2 soy burger 2 22 N male & female 2
*Simons 2000 [20] T 80 placebo 0 20 N post 8
Squadrito 2002 [21] T 54 G= 54 placebo 0 60 N female 24
*Urban 2001 [22] T 70 G = 42; D = 27 ISP 3 28 N elderly men 6
*Wangen 2001(I) [23] ISP 110–154 ISP
*Wangen 2001(II) 
[23]
ISP 54–76 6–8.2 18 NS post 4
* crossover design † 'T' = isoflavone tablet; 'ISP' = isolated soy protein ‡ 'G' = Genistein; 'D' = Daidzein; 'B' = Biochanin A; 'F' = Formononectin §'H' 
= hyperlipidemic subjects, 'N' = normolipidemic subjects; 'B' = both hyper- and normolipidemic subjects; 'NS' = not specified || 'pre' = 
premenopausal women; 'peri' = perimenopausal women; 'post' = postmenopausal womenNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/15
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heart disease (CHD) or cardiovascular accident (CVA),
may be selected as other endpoints in future trials. It may
help constructing convincing funnel plots with less heter-
ogeneity as trials accumulate.
Conclusions
Isoflavones tablets, up to 150 mg per day, had insignifi-
cant effects in lowering serum total cholesterol, LDL-cho-
lesterol and triglyceride. There was also insignificant
benefit over serum HDL-cholesterol. The results were con-
sistent when tablets were introduced as isolated genistein,
mixture of genistein and daidzein, or mixture of genistein,
daidzein, formononectin and biochanin A. No significant
effects were found among participants with normo- or
hyperlipidemia and women with pre- or postmenopausal
status. Isoflavones interventions in the forms of soy pro-
teins, such as isolated soy protein (ISP), soy diets or soy
protein capsule, were inconclusive due to inadequate
sample size, heterogeneity and presence of potentially
uncontrolled confounders.
List of abbreviations
'ISP' = isolated soy protein; 'TC' = total cholesterol; 'LDL'
= Low density lipoprotein cholesterol; 'HDL' = High den-
sity lipoprotein cholesterol; 'TG' = Triglycerides
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Table 2: Subgroup analysis of the effects of isoflavones on serum total cholesterol. Isoflavones were shown to have significant benefits 
when given in the form of ISP or soy protein capsule. Regardless the forms of prescription, isoflavones decreased serum total cholesterol 
among normolipidemic but not hyperlipidemic subjects.
Subgroup outcome No. of comparisons No. of subjects || Treatment effect on TC 
(mmol/L) ¶
Heterogeneity p-value §
Form of intervention †:
a.) isoflavones tablets 12 [8-10,12,13,16-18,20,21] 482 0.01 (-0.17, 0.18) 1.00
b.) ISP(+) 8 [14,15,22,23] 229 -0.11 (-0.21, -0.01)* 0.34
c.) soy protein capsule 1 [11] 78 -0.69 (-1.19, -0.19)* NA
d.) soy biscuit 1 [7] 20 -0.05 (-0.47, 0.37) NA
e.) soy burger 1 [19] 44 0.09 (-0.38, 0.56) NA
f.) Overall 21 [7-23] 853 -0.09 (-0.18, -0.01)* 0.77
Isoflavones mixture ‡:
G&D&B&F 5 [12,13,17,18] 214 -0.06 (-0.34, 0.21) 0.96
G&D 6 [9-11,16,19,22] 285 -0.22 (-0.41, -0.03)* 0.06
G 1 [21] 60 0.10 (-0.35, 0.55) NA
Isoflavones intake (mg per day):
< 50 3 [8,13,17] 132 -0.12 (-0.54, 0.29) 0.99
51–100 12 [8,10,12,14,15,17-23] 484 -0.10 (-0.21,0.01) 0.74
101 – 150 4 [9,11,15,23] 176 -0.10 (-0.24, 0.05) 0.09
Design :
parallel crossover 9 [8-14,21] 447 -0.08 (-0.27, 0.10) 0.48
a.) no washout 1 [22] 56 -0.43 (-0.73, -0.13)* NA
b.) washout mentioned 6 [15,19,20,23] 208 -0.07 (-0.17, 0.03) 0.91
Gender:
male 2 [7,22] 76 -0.30 (-0.54, -0.05)* 0.15
female 17 [8-11,13-18,20,21,23] 674 -0.07 (-0.17, 0.02) 0.89
Treatment length:
2–10 weeks 14[7,10,12,13,15-17,19,20,22,23] 541 -0.09 (-0.18, 0.00) 0.84
11–20 weeks 3 [11,14,18] 155 -0.22 (-0.52, 0.07) 0.07
21–30 weeks 4 [8,9,21] 157 0.02 (-0.28, 0.31) 0.96
Menopausal status:
pre-menopausal 3 [15,18] 80 -0.06 (-0.17, 0.06) 0.58
peri-menopausal 1 [11] 78 -0.69 (-1.19, -0.19)* NA
post-menopausal 13 [8-10,13,14,16,17,20,21,23] 516 -0.05 (-0.20, 0.10) 1.00
Subjects with:
normolipidemia 8 [11,12,15,18,19,21,22] 377 -0.11 (-0.21, -0.01)* 0.08
hyperlipidemia 3 [7,9,14] 105 -0.05 (-0.36, 0.26) 1.00
* statistically significant † 'ISP (+)' = isoflavone containing isolated soy protein; 'ISP (-)' = isoflavone depleting isolated soy protein ‡ 'G' = Genistein; 
'D' = Daidzein; 'B' = Biochanin A; 'F' = Formononectin § NA = not applicable || Since subjects acted as their own controls in a crossover trial, the 
'calculated' total number was thus doubled in a single pair comparison. ¶ 95% confidence interval in parenthesisNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/15
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